Benzinga · Oct 23, 2026
HC Wainwright & Co. Reiterates Buy on Oculis Holding, Maintains $39 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Oculis Holding (NASDAQ:OCS) with a Buy and maintains $39 price target.
OC
NASDAQ · OCS
Oculis Holding AG
Healthcare · Biotechnology
$8.26
Down-$0.55 (-6.66%)
Updated Nov 2, 2026, 10:57 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.09B
- P/E ratio
- -8.07
- Dividend yield
- 0.00%
- 52-week range
- $7.11 – $34.48
- Volume
- 309.7K
- Avg. volume
- 99.02K
Price performance · OCS
OCS price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
OCS closed at $8.26 after 20 trading sessions, down 3.50% for the selected period.
- Last close
- $8.26
- Period change
- -3.50%
- Period low
- $7.17
- Period high
- $8.72
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $8.19 | $8.84 | $8.19 | $8.26 | 309.7K |
| Oct 29, 2026 | $8.09 | $8.53 | $8.09 | $8.24 | 263.73K |
| Oct 28, 2026 | $7.80 | $8.05 | $7.72 | $7.98 | 220.03K |
| Oct 27, 2026 | $7.92 | $8.145 | $7.68 | $7.83 | 189.29K |
| Oct 26, 2026 | $7.88 | $8.025 | $7.65 | $7.96 | 206.97K |
| Oct 23, 2026 | $8.04 | $8.07 | $7.82 | $7.90 | 294.73K |
| Oct 22, 2026 | $7.77 | $8.3099 | $7.725 | $8.09 | 427.89K |
| Oct 21, 2026 | $7.54 | $8.02 | $7.40 | $7.87 | 324.1K |
| Oct 20, 2026 | $7.29 | $7.79 | $7.285 | $7.49 | 318.68K |
| Oct 19, 2026 | $7.25 | $7.46 | $7.15 | $7.32 | 288.39K |
| Oct 16, 2026 | $7.33 | $7.46 | $7.16 | $7.29 | 293.7K |
| Oct 15, 2026 | $7.25 | $7.60 | $7.15 | $7.40 | 559.21K |
| Oct 14, 2026 | $7.51 | $7.74 | $7.11 | $7.17 | 517.71K |
| Oct 13, 2026 | $7.84 | $7.84 | $7.32 | $7.62 | 320.23K |
| Oct 12, 2026 | $8.27 | $8.3252 | $7.85 | $7.88 | 283.96K |
| Oct 9, 2026 | $8.60 | $8.75 | $8.3001 | $8.34 | 162.06K |
| Oct 8, 2026 | $8.50 | $8.75 | $8.37 | $8.66 | 452.01K |
| Oct 7, 2026 | $8.83 | $8.83 | $8.35 | $8.50 | 173.69K |
| Oct 6, 2026 | $8.61 | $8.80 | $8.30 | $8.72 | 291.65K |
| Oct 5, 2026 | $8.79 | $9.00 | $8.56 | $8.56 | 242K |
Latest OCS news
The latest Smart Investors Daily articles mentioning OCS.
Stock researchCompany · Overview
Company
Market Activity
Research & News
OCS research
Overview
Company profile and research snapshot.
Company profile
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $43.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 23, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 18, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 14, 2026 | JP Morgan | Overweight | — |
| Aug 5, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 3, 2026 | JP Morgan | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 22, 2026
Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo Lower NfL and GFAP levels provide objective, complementary biological evidence of reduced neuroaxonal injury and suppressed reactive astrogliosis Biomarker results support previously reported functional (LCVA) +18-letter gains and structural retinal preservation at Month 3, reinforcing Privosegtor’s development for acute optic neuritis and acute mult
Yahoo · Oct 22, 2026
Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo Lower NfL and GFAP levels provide objective, complementary biological evidence of reduced neuroaxonal injury and suppressed reactive astrogliosis Biomarker results support previously reported functional (LCVA) +18-letter gains and structural retinal preservation at Month 3, reinforcing Privosegtor’s development for acute optic neuritis and acute mult
Benzinga · Oct 22, 2026
Oculis Says Phase 2 ACUITY Biomarker Data Show Privosegtor Lowered NfL, GFAP Versus Placebo In Optic Neuritis, Strengthening Confidence In PIONEER Registrational Program, Exploring Acute MS Relapses
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placeboLower NfL and GFAP levels provide objective, complementary biological
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
